MERIT MEDICAL SYSTEMS INC

Merit Medical Systems, Inc. announced positive results from the AVF cohort of the WRAP Global registry for its WRAPSODY™ Cell-Impermeable Endoprosthesis (CIE). The 6-month target lesion primary patency (TLPP) was 92.7% and access circuit primary patency (ACPP) was 76.7%, exceeding results from the pivotal WAVE trial. These real-world data, presented at the Controversies in Dialysis Access (CiDA) conference, demonstrate the device's favorable performance in routine clinical practice. The WRAPSODY CIE, approved by the FDA in December 2024 and Health Canada in April 2025, is designed to restore functionality in vascular access for hemodialysis patients.

Merit Medical Systems, Inc. announced that its management will participate in two upcoming investor conferences in August 2026. They are scheduled to hold fireside chats at both the Canaccord Genuity 46th Annual Growth Conference on August 11th and the Bank of America SMID Cap Conference on August 12th. Live audio webcasts and replays of these sessions will be accessible via the company's investor relations website.

Merit Medical Systems reported strong financial results for Q2 2026, with net sales increasing by 9.5% to $418.8 million and diluted EPS rising by 20.4% to $0.65. For the six months ended June 30, 2026, net sales grew 8.5% to $800.7 million and diluted EPS increased 29.1% to $1.33. The company also completed the acquisition of View Point Medical for an upfront payment of $90 million and divested its DualCap product line for $28 million, generating a pre-tax gain of $12.5 million.

Merit Medical Systems, Inc. announced strong financial results for the second quarter of 2026, exceeding expectations with reported revenue of $418.8 million, up 10% year-over-year, and GAAP diluted EPS of $0.65, up 20%. The company also saw improvements in both GAAP and non-GAAP operating margins. Following this performance, Merit Medical raised its full-year 2026 revenue guidance to $1.631-$1.643 billion and non-GAAP EPS guidance to $4.25-$4.35, reflecting confidence in continued growth and profitability. The company will host a conference call to discuss these results.

Merit Medical Systems, Inc. announced it will release its financial results for the second quarter ended June 30, 2026, after the stock market closes on Thursday, July 30, 2026. The company will also host an investor conference call on the same day at 4:30 p.m. Eastern Time. Details for pre-registration and accessing the live webcast will be available on Merit's website.

Merit Medical Systems, Inc. shareholders elected Scott R. Ward to the Board of Directors for a three-year term at the Annual Meeting on May 13, 2026. Shareholders also approved the 2026 Equity Incentive Plan (EIP) and the 2026 Employee Stock Purchase Plan (ESPP), authorizing 2,700,000 and 500,000 shares respectively. The Board adopted Fifth Amended and Restated Bylaws, updating provisions for remote meeting participation, electronic notices, universal proxy rules, and director/officer indemnification. Additionally, shareholders approved executive compensation and ratified Deloitte & Touche LLP as the independent auditor.

Merit Medical Systems, Inc. announced that shareholders elected Scott R. Ward to its Board of Directors for a three-year term at the annual meeting. Ward brings over 40 years of experience in the healthcare and medical device industry, including senior leadership roles at Medtronic and as CEO of Cardiovascular Systems, Inc. He will serve on the company's Governance and Sustainability and Finance and Operating Committees.

Merit Medical Systems, Inc. announced that its management will participate in the Bank of America 2026 Health Care Conference, taking place in Las Vegas, Nevada, from May 12-14, 2026. The management team is scheduled to host a fireside chat session on Tuesday, May 12th, at 3:00 pm Pacific Time. A live audio webcast of the session will be available on the company's investor relations website, with a replay accessible for approximately 90 days.

MERIT MEDICAL SYSTEMS INC reported strong first-quarter 2026 financial results with net income increasing significantly by 35.98% to $40.995 million and net sales growing 7.46% to $381.877 million. The company also completed the divestment of its DualCap® product line for $28 million, realizing a pre-tax book gain of $12.5 million. Additionally, the company has transitioned to a single operating segment and adjusted its product categories to Foundational and Therapeutic.

Merit Medical Systems, Inc. reported strong first-quarter 2026 financial results, with revenue increasing 7% to $381.9 million and GAAP EPS rising 39% to $0.68. The company also announced the divestment of its DualCap® product line for $28 million and the acquisition of View Point Medical for $140 million. Following these developments, MMSI updated its full-year 2026 revenue guidance to $1.612 - $1.634 billion, while maintaining its non-GAAP EPS guidance.